Cambridge biotech tracker · Boston
Monte Rosa Therapeutics
Listed on Nasdaq as GLUE, filed under SEC industry code 2836 (biological products). Fiscal year ends in December. Numbers below are from the company’s own SEC filings through Q3 '26.
- Cash & investments
- $578M
- Q3 '26 · Sep 30, 2026
- Burn per quarter
- $41.4M
- avg. operating cash flow, 4 qtrs
- Runway
- 3.5 yrs
- 3+ years
- Net loss
- +$3.1M
- Q3 '26 · net income
- R&D expense
- $45.4M
- 81% of opex
- Raised, last 4 qtrs
- +$362M
- net financing cash flow
- Next readout
- Oct 2027
- Phase 2 · cash past the catalyst
Cash & investments
Quarter-end balance
Operating cash flow
Per quarter; below zero is burn
R&D expense
Per quarter
Two views of the runway
Compare across the clusterThe outside view
3.5 years
Cash at Q3 '26 divided by the average burn of the last four quarters, $13.8M a month.
Management’s own date
12+ months
The latest filing states only the going concern minimum, that cash covers at least twelve months from issuance. No sharper date was filed.
Cash against the calendar
What the runway has to reach.
Oct 2027estimated
Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
Castration-Resistant Prostate Cancer (CRPC) · Castration-Resistant Prostate Cancer · Prostate Cancer
NCT07745361 on ClinicalTrials.govDoes the cash reach it?
Cash past the catalyst
- Runway
- 3.5 years
- Time to the date
- 11 months
It is about 11 months out. At the current burn there is roughly 31 months of cash left on the far side of it, which is enough room to raise on the result rather than ahead of it.
Pipeline
3 active trials, through phase 2.
Phase 1/2 · 1Phase 1 · 1Phase 2 · 1
| Study | Phase | Status | Enrolled | Primary completion |
|---|---|---|---|---|
| Study of Oral MRT-2359 With Apalutamide in Prostate CancerNCT07745361 · Castration-Resistant Prostate Cancer (CRPC), Castration-Resistant Prostate CancerPhase 2Oct 2027est. | Phase 2 | Recruiting | ||
| Study of Oral MRT-2359 in Selected Cancer PatientsNCT05546268 · NSCLC, SCLCPhase 1/2May 2026est. | Phase 1/2 | Active, not recruiting | ||
| A First-in-human, 3-part Study of MRT-8102 in Healthy Participants and Participants at Cardiovascular Risk With Elevated CRPNCT07119125 · Healthy Volunteers, Elevated CRPPhase 1Jul 2026est.· not a catalyst | Phase 1 | Active, not recruiting |
Interventional studies where this company is the lead sponsor, from ClinicalTrials.gov. Primary completion is when the last patient is measured on the primary endpoint, which is when the data exists rather than when it is announced. Extension, rollover and healthy-volunteer studies are listed but marked as non-catalysts, because they finish long after the result that mattered. Sponsors revise these dates as enrollment moves, so an estimate is a plan rather than a promise.
The controller’s read
What the filings say.
Generated from the numbers above using the same questions I ask when I open a client’s books: how long the cash lasts, what is driving the gap between loss and burn, and where the accounting judgment sits.
Get this read on your companyThe cash clears the next catalyst
The next dated event is a phase 2 readout in Oct 2027, about 11 months out. That leaves roughly 31 months of cash afterwards, which is the position you want: the raise can be negotiated on the data instead of on the calendar.
About 3.5 years of runway
Cash and investments of $578M at Q3 '26 against an average operating cash burn of $41.4M per quarter over the last four reported quarters runs out around March 2030. More than two years of runway means the finance conversation is about deployment, not survival.
Cash position up $206M since Q4 '24
Net financing inflows of $362M over the last four quarters, from equity, debt, or ATM sales, more than covered operating burn. The balance is the number the board watches; the trend is the number the auditors watch.
R&D is 81% of operating expenses
$45.4M of R&D against $56.3M of total operating expenses in Q3 '26, with G&A at $10.9M. For a clinical-stage company, the accounting questions live inside that R&D line: CRO and CMC accruals, milestone recognition, and what gets capitalized versus expensed under ASC 730.
$21.1M of deferred revenue on the balance sheet
Usually an upfront collaboration or license payment that is recognized as obligations are satisfied. It is cash already received, so it supports runway without showing up as revenue yet.
Accumulated deficit of $562M
Total losses since inception. It is also roughly the size of the net operating loss carryforward the tax provision has to track, subject to Section 382 limits after each ownership change.
Quarterly detail, eight quarters
| Quarter | Cash & inv. | Op. cash flow | Net income | R&D | G&A | Revenue | Stock comp | Financing |
|---|---|---|---|---|---|---|---|---|
| Q4 '24 · Dec 31, 24 | $372M | $129M | $13.4M | $38.9M | $8.8M | — | $4.5M | $608K |
| Q1 '25 · Mar 31, 25 | $326M | −$45.5M | $46.9M | $32.2M | $8.7M | — | $5.3M | $14K |
| Q2 '25 · Jun 30, 25 | $291M | −$34.7M | −$12.3M | $30.7M | $8.1M | — | $4.9M | $365K |
| Q3 '25 · Sep 30, 25 | $391M | $100M | −$27.1M | $36.7M | $9.1M | — | $4.4M | $348K |
| Q4 '25 · Dec 31, 25 | $377M | −$43.0M | −$46.1M | $42.0M | $10.5M | — | $4.3M | $29.6M |
| Q1 '26 · Mar 31, 26 | $666M | −$37.4M | −$44.5M | $44.1M | $10.2M | — | $5.9M | $328M |
| Q2 '26 · Jun 30, 26 | $621M | −$44.1M | −$43.4M | $48.0M | $10.1M | — | $6.0M | $3.2M |
| Q3 '26 · Sep 30, 26 | $578M | −$41.0M | $3.1M | $45.4M | $10.9M | — | $6.3M | $568K |
Source: SEC EDGAR XBRL company facts, latest filed value for each period. Fourth quarters are derived from annual less nine-month figures; quarterly cash flows are derived from year-to-date amounts. Not investment advice. If a figure disagrees with the filing, the filing is right.